API | tarextumab

tarextumab Report issue

Biologics mAb Experimental

AACT ChEMBL DrugBank MeSH

Active Ingredient History

NOW

Tarextumab is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In January 2015, the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer. Two early stage clinical trials have reported encouraging results. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
tarextumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Neurogenic locus notch homolog protein 2 (Homo sapiens) ^UniProt
- Neurogenic locus notch homolog protein 3 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

omp-59r5 | tarextumab

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 1/Phase 2)

Small Cell Lung Carcinoma (Phase 1/Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 3
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue